These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21774796)

  • 1. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study.
    Liu Q; Zhou H; Liu L; Chen X; Zhu R; Cao Z
    BMC Bioinformatics; 2011 Jul; 12():294. PubMed ID: 21774796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (Multiple QSAR) Method.
    Wei Y; Li W; Du T; Hong Z; Lin J
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
    Gallay PA; Bobardt MD; Chatterji U; Trepanier DJ; Ure D; Ordonez C; Foster R
    PLoS One; 2015; 10(8):e0134707. PubMed ID: 26263487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR and docking studies of HCV NS3 serine protease inhibitors.
    da Cunha EF; Matos KS; Ramalho TC
    Med Chem; 2013 Sep; 9(6):774-805. PubMed ID: 23140577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
    Qin Z; Wang M; Yan A
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The design of drugs for HIV and HCV.
    De Clercq E
    Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.
    Tsou LK; Dutschman GE; Gullen EA; Telpoukhovskaia M; Cheng YC; Hamilton AD
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2137-9. PubMed ID: 20202840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
    Flanagan S; Crawford-Jones A; Orkin C
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV therapy in HIV-infected patients.
    Sulkowski MS
    Liver Int; 2013 Feb; 33 Suppl 1():63-7. PubMed ID: 23286848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
    Han J; Lee HW; Jin Y; Khadka DB; Yang S; Li X; Kim M; Cho WJ
    Eur J Med Chem; 2020 Feb; 188():112031. PubMed ID: 31923861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
    Zhang J; Mulvenon A; Makarov E; Wagoner J; Knibbe J; Kim JO; Osna N; Bronich TK; Poluektova LY
    Biomaterials; 2013 May; 34(15):3846-57. PubMed ID: 23403120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling anti-HIV compounds: the role of analogue-based approaches.
    Srivastava HK; Bohari MH; Sastry GN
    Curr Comput Aided Drug Des; 2012 Sep; 8(3):224-48. PubMed ID: 22734706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The QSAR Paradigm in Fragment-Based Drug Discovery: From the Virtual Generation of Target Inhibitors to Multi-Scale Modeling.
    Kleandrova VV; Speck-Planche A
    Mini Rev Med Chem; 2020; 20(14):1357-1374. PubMed ID: 32013845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute and chronic HCV infection in persons with HIV coinfection.
    Sulkowski MS
    J Hepatol; 2014 Nov; 61(1 Suppl):S108-19. PubMed ID: 25443339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.